Address And Details

100 Vanguard Blvd. , Malvern, PA 19355
Fund Manager Joseph Marvan
Manager Tenure 2 Years 5 Months

Strategy And Objective

The Fund seeks to provide a moderate level of current income. The Fund invests at least 80% of its assets in Government National Mortgage Association (GNMA) pass-through certificates, which are fixed income securities representing part ownership in a pool of mortgage loans supported by the full faith and credit of the U.S. government. The balance of the Fund s assets may be invested in other types of securities, such as U.S. Treasury or other U.S. government agency securities, including pass-through certificates, as well as in repurchase agreements collateralized by such securities. Securities issued by most U.S. government agencies, other than the U.S. Treasury and GNMA, are neither guaranteed by the U.S. Treasury nor supported by the full faith and credit of the U.S. government. The Fund s dollar-weighted average maturity depends on homeowner prepayments of the underlying mortgages. Although the Fund does not observe specific maturity guidelines, its dollar-weighted average maturity will normally fall within an intermediate-term range (3 to 10 years).

Net Asset Value

as of 5:59 PM ET 10/18/2021


  • 1 Week
  • 0.00%
  • 1 Month
  • -0.56%
  • 3 Months
  • -0.38%
  • 1 Yr Return
  • -1.12%
  • 5 Yr Return
  • -2.40%

Equity Sector Breakdown

ConsumerDurables n/a
Energy n/a
Finance n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Bonds 96.85%
Cash 22.63%
Stocks 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Other -19.47%
Total Net Assets 16.85 B

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha 1.28 -0.03 0.30
Beta 0.32 0.45 0.56
R Squared 0.37 0.54 0.60
Std Deviation 1.79 1.99 2.16
Sharpe Ratio 1.49 0.41 n/a

Purchase Information

as of 5:52 PM ET 10/15/2021
Minimum Initial $50000
Minimum Additional $1
Minimum Initial IRA $0


Timeframe Average Annual Current Performance Monthly As Of 09/30/2021 Average Annual Current Performance Quarterly As Of 09/30/2021 Avg Annual Current Performance Monthly As Of 09/30/2021 Avg Annual Current Performance Quarterly As Of 09/30/2021
1 Year
  • -0.06%
  • -0.06%
-0.06% -0.06%
3 Year
  • +3.68%
  • +3.68%
+3.68% +3.68%
10 Year
  • +2.35%
  • +2.35%
+2.35% +2.35%
Life Of Fund
  • +4.23%
  • +4.23%
+4.23% +4.23%

Top 10 Holdings

Symbol Company Name % Of Assets


Recent Articles from TheStreet

After Red-hot IPO, Chinese Biotech Firm Kintor Eyes Blockbuster Drugs For Prostate Cancer, Sex Hormone-related Hair Loss

Atea Pharma Stock Plunges After COVID Treatment Trial Disappoints; Merck Jumps

Atea Pharmaceuticals could shed more than $2 billion in value Tuesday after the drugmaker said a mid-stage trial of its developing COVID treatment failed to meet expectations.

What to know about Cloudflare's Upcoming IPO

Investing in the Cloud: Consider Cloudflare and Digital Ocean

Cloud-software growth stocks have been a bright spot in an uncertain market. Investors might look closely at Cloudflare and Digital Ocean.

Philip Morris International Lead

Philip Morris Ekes Out Third-Quarter Earnings Beat

Philip Morris posts a third-quarter earnings beat as sales of its smokeless non-tobacco products continue strong, though cautions on supply chain impact.

The Travelers Companies Lead

Travelers Posts Third Quarter Earnings Beat on Record Net Written Premiums

Travelers Companies posts third-quarter earnings that exceed analysts’ forecasts as a drop in what it calls ‘catastrophic losses’ offsets record net written premiums.

Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters

Stock Market Today: Dow Gains On Earnings Strength; Housing Starts Disappoint

Solid third quarters continue to power stocks higher Tuesday, even as growth and inflation signals remain stubbornly persistent as oil prices top $85 a barrel in overnight trading.

Procter & Gamble Is Under Siege From an Activist Investor

Procter & Gamble Stock Slips After Q1 Earnings Beat; 2022 Forecast Unchanged

Procter & Gamble held its 2022 forecasts in place, seeing sales growth of between 2% and 4%, following stronger-than-expected first quarter earnings.

No More Tears for Johnson & Johnson?

Johnson & Johnson Stock Gains as Vaccine Sales Boost Q3 Earnings, 2021 Forecasts

Johnson & Johnson said it sees 2021 vaccine sales of $2.5 billion, with overall revenues rising to between $94.1 billion to $94.6 billion, following its Q3 earnings beat.

Stock Market Lead

Stocks Gain, SEC GameStop Report, Rent The Runway IPO - 5 Things You Must Know

Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.